Company news
Argenx Se (EURONEXT:ARGX) news
Every Argenx Se press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
July 27, 2026
argenx to Host Autoimmune Myositis R&D Webinar
June 23, 2026
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
June 3, 2026
argenx to Host Myositis R&D Webinar on June 23, 2026
May 28, 2026
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
May 8, 2026
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
argenx to Present at BofA Securities 2026 Health Care Conference
May 6, 2026
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
May 6, 2026
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
April 30, 2026
argenx announces Annual General Meeting of Shareholders on May 6, 2026
March 20, 2026
Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics
March 16, 2026
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength ...
March 6, 2026
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
February 26, 2026
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
February 26, 2026
argenx to Present at TD Cowen 46th Annual Healthcare Conference
February 23, 2026
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
February 19, 2026
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
January 13, 2026
argenx Highlights 2026 Strategic Priorities
January 12, 2026
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
argenx Announces Leadership Transition Marking Next Evolution of Growth
January 5, 2026
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
December 15, 2025
argenx Announces Results of Extraordinary General Meeting of Shareholders
November 18, 2025
/C O R R E C T I O N from source -- argenx Canada Inc./
November 5, 2025
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
October 30, 2025
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
October 29, 2025
argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
October 23, 2025
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
October 15, 2025
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
October 3, 2025
FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations
September 18, 2025
Hemab Therapeutics Expands Leadership with Appointment of Anant Murthy, PhD, as Chief Operating Officer
September 2, 2025
argenx to Present at Upcoming Investor Conferences
August 28, 2025
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
August 25, 2025
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
August 19, 2025
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
August 12, 2025
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
July 31, 2025
argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
July 24, 2025
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
June 30, 2025
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
June 20, 2025
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
June 10, 2025
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
June 3, 2025
argenx Announces Results of Annual General Meeting of Shareholders
May 28, 2025
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
May 8, 2025
argenx to Present at BofA Securities 2025 Health Care Conference
May 6, 2025
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
May 1, 2025
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Poly...
April 28, 2025